Community post

Jingen Zhu (The Catholic University of America, Washington, DC) and colleagues published a new preprint describing the use of CRISPR-engineered phage T4 as a universal platform to produce vaccines against SARS-CoV-2. They found high levels of antibody and T cell-mediated immune response when they tested the construct on rabbit and mouse models. Beyond SARS-CoV-2, this platform has the potential to generate cost-effective and efficient vaccine candidates against any future pathogen.